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Exosomes are extracellular vesicles with a diameter of 30–100 nm,
which are released into the extracellular space by fusion of multivesicular and plasma membranes. These vesicles actually play a
distinct role in cell communication, although they were considered
as membrane debris in the past. The endosomal sorting complex
required for transport (ESCRT)-dependent and ESCRT-independent
mechanisms are currently considered to be involved in the sorting
of exosomes, and the release of exosomes is related to the members
of Rab protein family and SNARE family. In recent years, the
therapeutic potential of exosomes has become apparent. For example,
via the direct transplantation of exosomes, the ischemic area after
stroke is reduced, and the neurological function is improved
significantly. Furthermore, they can be used as effective drug
delivery vehicles due to their unique characteristics such as low
immunogenicity and nanometer size. In conclusion, exosomes
provide a cell-free treatment for ischemic stroke.
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1

Introduction

Communication between cells has always been
considered as the basis for the completion of
life activities. Exosomes were originally treated
as waste products of cells [1], but gradually discovered to be involved in the release mechanisms,
which fully affirmed them as important inter-cell
communication substances [2]. However, until
today the mechanism of exosome fusion has not
been fully studied, so it is worth exploring their
biogenesis.

Exosomes, in addition to being secreted by
different types of cells [3], are also present in body
fluids, including cerebrospinal fluid and semen.
Many substances from parental cells, including
miRNAs and proteins [4], are contained in
exosomes, participating in the formation and
development of many diseases [5]. For example,
the development of Parkinson’s disease is associated with the spread of α-synucleins, which
can be found in exosomes [6].
Exosomes promote drug delivery system reforming as natural carriers. They can not only be
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exploited directly as some potential agents, but
essentially, they can also carry other substances
such as small molecule drugs into recipient cells
[7]. Exosomes are promising in the treatment of
neurological diseases such as post-stroke ischemic
areas, because they have been shown to cross the
blood–brain barrier and peripheral organ retention
[8]. In this review, we will use stroke treatment as
an example to describe the therapeutic potential
of exosomes.

2

Biology of exosomes

2.1 Exosomes composition
Intercellular communication is an essential
hallmark of multicellular organisms, and can
be mediated through cell–cell contact directly
or transfer of secreted molecules [2]. Exosomes
are endogenous nanovesicles whose interaction
between cells plays a key role by transmitting
functional genetic information and proteins [9].
Exosomes were first discovered in 1983, but
were originally thought to be wastes released
by stripping the serosa [4]. However, there has
been a surge of interests in exosomes in the past
few decades, and after long-term exploration the
exosomes contents are found to be lipids, proteins,
nucleic acids [mRNA, microRNA (miRNA), long
non-coding RNA (lncRNA), and rare DNA] [10].
In addition, mounting evidence has shown that
these vesicles are important messengers between
cells, because they can store and transmit cellular
signals [10]. In recent years, these vesicles have
been shown to affect the physiological functions
of adjacent recipient cells in different ways. For
example, extracellular vesicles can provide
new genes for recipient cells, giving them new
properties [3].
Exosome is a type of extracellular vesicles, which
includes apoptotic bodies and microvesicle [11].
Both exosomes and microvesicles are vesicles
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enclosed by a lipid bilayer, but their membrane
components are not identical because of their
origins [1]. Exosomes are derived from the
endocytic pathway, but microvesicles are directly
budding from the plasma (Fig. 1). In addition to
the secretory pathway, the size is usually different
between them. Microvesicles are 100 nm to 1 μm
in diameter, while exosomes are 30 nm to 100 nm
[12]. Moreover, exosomes come from a wide range
of sources, and can be found in physiological fluids
such as urine, lymph, amniotic fluid, malignant
pleural effusion, milk, semen, saliva, and plasma
[13]. Almost all mammalian cell types, including
primary cells of the immune, stem cells, nervous
systems, and many cancer cell lines, can secrete
exosomes. Importantly, apart from mammalian
cells, exosomes have also been identified in lower
eukaryotes and prokaryotes [1].
2.2 Exosome cargoes
Studies have shown that some certain proteins
or protein families are expressed in exosomes of

Fig. 1

Biogenesis of extracellular vesicles and their interactions

with recipient cells. Reproduced from Ref. [1] with permission of
Springer Nature.
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different cell origins, but the specific function of
these conserved proteins is unknown at present,
which may be related to cell origin. These ubiquitous proteins include multivesicular-associated
proteins [e.g. ALG-2 interacting protein X (ALIX),
tumor susceptibility gene 101 (TSG101), endosomal
sorting complex required for transport (ESCRT)],
metabolic enzymes [e.g. glyceraldehyde-3phosphate dehydrogenase (GAPDH), peroxidase,
pyruvate kinase, lactate dehydrogenase], signal
transduction proteins (e.g. protein kinases, heterotrimeric G proteins), and membrane transport
proteins (e.g. Rab protein, annexin). Exosomes
also contai molecular chaperones. Heat shock
protein (Hsp) 70 and Hsp90 are thought to be
involved in antigen presentation, because they
can bind antigenic peptides and participate in
loading peptide onto major histocompatibility
complex (MHC) molecules [14]. Meanwhile,
tetraspanins [15] [e.g. cluster of differentiation
(CD) 9, CD63, CD81, CD82] existing in exosomes
that are secreted by almost all types of cells can
mediate cell migration, fusion, adhesion, and
signal transduction.
Some proteins with special functions are also
present in exosomes except for ubiquitous proteins.
These specific proteins contained in exosomes
can reveal which mother cells they are from.
For example, exosomes derived from intestinal
epithelial cells contain various metabolic enzymes
[16]; exosomes derived from T cells have T
cell surface receptor proteins; and the ones from
dendritic cells contain a large number of proteins
associated with antigen-presenting cells, such as
MHC class I molecules, MHC class II molecules,
and costimulatory molecules CD80 and CD86 [17].
These proteins can be used as markers to provide
a basis for early diagnosis of disease, such as
tumors. In addition, the production of specific proteins is associated with the secretory pathway
of exosomes. The secretion of general proteins
in the cells is carried out through Golgi complex,

which is, the secretions are synthesized and stored
in the Golgi complex through the endoplasmic
reticulum, and the cells are stimulated by the Golgi
complex membrane and the cell membrane after
receiving the external signal. However, unlike the
general secretory pathway of intracellular proteins,
exosomes are small vesicles that are released by
fusion of multivesicular membrane with plasma
membrane. The surface of the exosomes has
special protein compositions that come from
different secretory pathways, but it lacks certain
membrane proteins with high expression on the
surface of the cell membrane, due to the endoplasmic reticulum which does not contain proteins.
For example, dendritic cells express high levels
of Fc receptors, but the surface of the exosomes
from dendritic cells does not.
Lipid, including phosphatidylserine, sphingomyelin, and cholesterol, is an important component
of exosomes [18]. The lipid molecules contained
in the exosomes not only maintain the shape
of exosomes, but also can be used as signaling
molecules in many biological processes, such as
passing intermediate signaling molecules like
prostaglandins, phosphate kinase C and D [19].
The membrane structure of the exosomes is similar
to the cell membrane, and the phospholipid bilayer
can protect the exosomes from degradation by
enzymes in the extracellular environment, and
further enhance their ability to adsorb target cells.
Exosomes also contain numerous functional
RNA molecules (e.g. miRNAs, lncRNAs) that
reflect the physiological and pathological of the
cells from which they originate [18]. These genetic
substances are incorporated into the target cells
via the fusion of exosomes with the target cell
membranes, thereby exerting the function of
genetic information exchange [20, 21]. For example,
a kind of miRNA can regulate gene expression by
being bound to the 30 untranslated regions of the
target mRNA, resulting in translational inhibition
and/or mRNA degradation. Like miRNAs,
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lncRNAs do not encode proteins, but are expressed
specifically at different tissues and developmental
stages, indicating that they have important
biological implications. Exosomes do not contain
mitochondria, lysosomes, or other organelles and
nucleuses, because exosomes are budded from the
capsular sag and encapsulated in processing lipids,
proteins, and genetic materials in the cytoplasm.
Studies have shown that tumor cells secrete
microparticles containing genomic DNA, c-Myc
single-stranded DNA, and cDNA.
2.3 Isolation and identification of exosomes
Obtaining high-quality exosomes is the key to
better analyzing their contents and functions. The
separation and purification of exosomes have been
a hindrance for the study of their characters,
however, efficient methods for separating exosomes
are rapidly improving. Ultracentrifugation is the
most commonly used method for purification
of exosomes, and vesicle particles of the desired
size can be obtained by increasing the speed of
centrifugation. Johnstone et al. originally initiated
the centrifugation method for the separation of
exosomes in reticulocyte tissue culture fluid [22],
and then they improved the method on that basis.
The tissue supernatant was centrifuged at 300 × g,
1200 × g, and 10,000 × g for 5, 20, and 30 minutes
respectively to remove the doped cell debris, dead
cells, and detached bodies. Finally, exosomes
were isolated by high-speed ultracentrifugation
(110,000 × g) for 1 h, the purity was increased
twice [23]. For the production of a large number
of exosomes, the steps involving 1200 × g,
10,000 × g of centrifugation can be replaced by
filtration on 0.22 μm in order to eliminate large
fragments [23]. The sucrose density gradient
centrifugation method is an improved method
based on ultracentrifugation to further improve
the purity of exosomes, because the ultracentrifugation does not clearly distinguish exosomes
from other small vesicles or large protein
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aggregates. Ultracentrifugation is followed by
linear or non-linear sucrose gradient centrifugation
depending on the density of the exosomes
ranging from 1.13 g/mL to 1.19 g/mL, then the
contaminating materials, including nucleosome
fragments that are released by apoptotic cells
or protein aggregates, can be separated easily
from exosomes by flotation on sucrose gradients
[24–26]. The re-suspended pellet was wrapped
with a sucrose gradient, and then centrifuged at
100,000 × g for 5 h. The layers were collected, and
the expression of exosome marker molecules such
as CD63 and CD8l in the solution was analyzed
by Western blotting. In this case, the density layer
of exosomes can be determined. In recent years,
researchers have also described a PEG-based
ExtraPEG technology that accumulates exosomes
rapidly and inexpensively by small volume
ultracentrifugation after centrifugation of large
volumes of culture medium. ExoQuick, Pure-Exo
and Total Exosome Isolation kits can be used to
isolate exosomes [27–29]. In addition, integrated
on-chip isolation and in situ electrochemical
analysis of exosomes from serum, a two-stage
microfluidic platform (exoPCD-chip) [30] can
promote the capture efficiency of exosomes
without any surface modifications via an improved staggered Y-shaped micropillars mixing
pattern (Fig. 2).
The existing separation techniques are mainly
based on the size and structure of exosomes,
so it is difficult to completely distinguish them
from other vesicles or macromolecular protein
complexes, and requires identification [2]. The
exosomes can be identified by nanometer particle
tracer analysis (NTA) to measure particle size
[31], by Western blotting and flow cytometry to
analyze signature proteins (CD9, CD63, CD81,
HSP90, etc.). Electron microscope can directly
observe the morphology and particle size of
exosomes, but the testing has higher requirements
on the preparation of the sample, sample separation method and sample properties, which may
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Fig. 2 (A) Bright-field microscope image of Tim4 beads manipulated
in the microfluidic channel. (B) Fluorescence images of the DiI labeled
exosomes in the microfluidic channel. (C) SEM image of the array of
Y-shaped PDMS micropillars. (D) TEM image of exosomes captured
by the ExoPCD-chip. qNano analysis of the size distribution of
exosomes purified by the ExoPCD-chip (E) and commercial exoEasy
Kit (F). Reproduced from Ref. [30] with permission of The American
Chemical Society.

affect the the results. In the research field of
exosomes, NTA technology has been used as
one of the methods for characterizing exosomes.
Compared with other characterization methods,
the sample processing of NTA technology is
simpler, which can ensure the original state of
exosomes, and the operation is quicklier. In
addition, western blotting is used to detect
exosome surface proteins (e.g. CD63, CD8, TSG101,
flotillin-1, ALIX, CD9, CD81, CD82) to improve
the reliability of the exosome characterization.

3

Exosomes biogenesis

3.1 ESCRT-independent
mechanisms

and

-dependent

In the process of maturation into multivesicular
endosome (MVE), exosomes are produced as
intraluminal vesicles (ILVs) in the lumen of the
endosomes, a process involving a specific “sorting
machine”. In recent years, ESCRT on exosomes
formation has received increasing attention. A

device consisted of four main compounds and
several auxiliary components is positioned in the
cytoplasm side of the endocytosis, and its main
role is to form the precursor of exosomes by
sorting specific components into the ILVs. ESCRT
contains four complexes (ESCRT-0, I, II, III) and
accessory proteins (VPS4, Vta1, ALIX, etc.), with
each component playing different roles. ESCRT-0
identifies and separates the ubiquitination of
endocytic membrane transmembrane proteins;
ESCRT-I synergizes with ESCRT-II to encapsulate
endosomal membrane with specific contents
through inward bud; the ESCRT-III is responsible
for cutting the vesicles [14]; finally, the ATPase
vacuolar protein sorting 4 (VPS4) was recruited
in bud necks by interacting with the ESCRT III
subunit protein, and it can hydrolyze ATP under
the regulation of positive regulators Vta1, negative regulators IST1 [32], Did2 and VPS60 to
obtain energy to depolymerize ESCRT from the
endocytic membrane and enter the cytoplasm
[33]. Meanwhile, the cycle acts on a new round
of multivesicular formation and protein sorting
processes. In addition, the study found that the
ESCRT-0, I, II and the Alix protein, all of which
seem to be involved in the disruption of the
plasma membrane, but they actually only play a
role in recruiting ESCRT-III complex.
Interestingly, some researchers have found
that CD63 markers associated with exosomes still
exist despite knocking out ESCRT complexes,
suggesting that exosomes can also be formed in
an ESCRT-independent manner. The ceramides,
transmembrane 4 superfamily tetraspanins and
heat shock proteins assisted ILVs and multivesicular body (MVB) with their formation [34].
Neutral sphingomyelinase hydrolyzes sphingomyelin to form ceramide, and both the ceramide
production and the exosomes were significantly
reduced when neutral sphingomyelinase is inhibited by the enzyme inhibitor GW4869 [35]. The
constant supply of S1P catalyzed by SphK2 allows
the S1P receptor to remain active on MVE, and
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this continuous activation of the S1P receptor is
required for cargo sorting into the ILV, while
the intervention of FTY720 leads to inhibition
of the S1P signal on the MVE, and prevents the
maturation of exosomes [36]. As a regulator of ILV
germination and exosome production, the small
G protein ADP ribosylation factor 6 (ARF6) on
the endocytic membrane activates phospholipase
D2, while phospholipase D2 can invade the
cytoplasmic membrane and produce MVB
and ILVs [34]. In addition, tetraspanins are also
frequently found to play an important role in the
formation of LVs and exosomes [37].
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with the cell surface. The above processes are
related to the cytoskeleton, molecular switches,
molecular motors, and fusion mechanisms [2, 41].
The Rab protein family is the largest subfamily of
the Ras superfamily, and includes small GTPbinding proteins. As a molecular switch for vesicle
trafficking, Rab proteins control the transport
of intracellular vesicles (Fig. 3), such as vesicle

3.2 Mechanism of secretion of exosomes to the
extracellular
The fusion process of the vesicles produced by
the donor membrane with the receptor membrane
is an important step in the vesicle transport
pathway, which includes two processes: the vesicle
specifically recognizes the target membrane, and
the vesicle fuses with the target membrane to
release the contents. SNAREs have been found
to be involved in this step, which includes two
contents: the vesicular SNAREs (VAMPs) that is
localized in the donor membrane, and the target
SNAREs (t-SNAREs) that is localized in the
acceptor compartment [38]. Syntaxin 3 (STX3)
plays a role in the recruitment of exosomes, the
STX3-5r mutation as a major dominant negative
inhibitor is effective in reducing the number of
Human cytomegalovirus (HCMV) particles in
polarized epithelial cells. These results indicate
that STX3 plays a role in the transport of vesicle
contents [39]. Studies by Gross et al. showed that
in HEK293 cells, the SNARE protein component
YKT6 promoted the production of exosomes
loaded with WNT3A morphogens [40].
Secretion of exosomes involves the machineries
that separate microvesicles (MVs) from plasma
membranes, the movement of secreted MVs to
the periphery of the cell, and the fusion of vesicles
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Fig. 3 Rab GTPase functions in vesicle trafficking. Distinct
membrane trafficking steps that can be controlled by a Rab GTPase
and its effectors (indicated in orange). a. An active GTP-bound Rab
can activate a sorting adaptor to sort a receptor into a budding
vesicle. b. Through recruitment of phosphoinositide (pi) kinases
or phosphatases, the PI composition of a transport vesicle might
be altered (the conversion of PI-x into PI-y) and thereby cause
uncoating through the dissociation of PI-binding coat proteins.
c. Rab-GTPases can mediate vesicle transport along actin filaments
or microtubules (collectively refered to as cytoskeletal tracts) by
recruiting motor adaptors or by binding directly to motors. d. Rab
GTPases can mediate vesicle tethering by recruiting rod-shaped
tethering factors that interact with molecules in the acceptor
membrane. Such factors might interact with SNAREs and their
regulators to activate SNARE complex formation, which results in
membrane fusion. e. Following membrane fusion and exocytosis,
the Rab GTPase is converted to its inactive GDP-bound form through
hydrolysis of GTP, which is stimulated by a GTPase-activating
protein (GAP). Targeting of the Rab–GDP dissociation inhibitor (GDI)
complex back to the donor membrane is mediated by interaction
with a membrane-bound GDI displacement factor (GDF). Conversion
of the GDP-bound Rab into the GTP-bound form is catalyzed by
a guanine. nucleotide exchange factor (GEF). Reproduced from
Ref. [42] with permission of Springer Nature.
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formation, transportaton, adhesion, anchoring,
and fusion, suggesting that Rab may be involved
in the secretion of exosomes [42]. The expression
of Rab11 regulates exosome secretion by reticulocyte cell lines, which proves that Rab GTPases
plays a role in exosomes secretion.
Abrami et al. demonstrated that SNX3, TSG101,
and ALIX are involved in the biosynthesis of LFloaded exosomes in human retinal pigmented
epithelial 1 (RPE1) cells, and the Rab11 and Rab35
actually act on exosomes release rather than
Rab27, thus anthrax toxins through the secretory
pathway spread to distant cells [43]. Studies have
found that Rab27a and Rab27b can promote the
distribution of MVEs to the periphery of cells,
and play a role in the docking of MVEs and
plasma membrane. In addition, knockdown
of Rab27a and Rab27b significantly reduced the
number of HeLa cell exosomes; MVEs in total
internal reflection fluorescence (TIRF) microscope imaging showed that silencing of Rab27b
significantly reduced MVEs density [44]. In
primary oligodendrocytes, silencing of Rab35 can
interfere with glutamate-dependent release of
proteolipid protein (PLP) and ALIX [45]. Notably,
studies have shown that the effects of GTPases
can be complementary, for instance, the release of
exosomes is only partially affected by selective
inactivation of Rab11, Rab27, and Rab35.

4

Therapeutic potential

Ischemic stroke is the leading cause of chronic
disability worldwide [46]. Recombinant tissue-type
plasminogen activator (alteplase) was approved
by the US Food and Drug Administration
(FDA) in 1996. So far, it still remains the only
medication proven to affect outcomes when given
in the hyperacute time frame after ischemic
stroke [47, 48]. The regression line indicated that
the treatment would be effective if patients are
treated with TPA within 4.5 hours after stroke,

while it would be ineffective after 4.5 hours, even
harmful after 6 hours [49]. “Time is the brain”,
but the rigorous 4.5-hour time window often
prevents this treatment from being fully utilized
[50]. Intravascular thrombectomy can extend the
treatment window and reduce the risk of intracranial bleeding. However, due to vessel tortuosity,
the stenosis of the arteries, and the inaccessibility
of blood clots, the mechanical recombination
device also showed limitations [10]. Therefore,
it is crucial to find a safer and more effective
treatment for stroke.
4.1 Exosomes transplantation therapy directly
The core objective of regenerative medicine is to
repair or regenerate various tissues and organs,
and to address tissue and organ functional
disorders caused by diseases, trauma, aging, or
genetic factors [51]. The functional recovery
of cell therapy in regenerative medicine plays
an extremely important role, for example, the
inflammation can be effectively controlled, and the
nerve function is restored after the transplantation
of cells into damaged region. Stem cells have
become the primary choice for transplantation
therapy because of their “infinite” proliferation
and multi-prospective differentiation potential.
Moreover, stem cell transplantation therapy has
been shown to promote the recovery of damaged
tissues [52, 53], including spinal cord, heart, brain,
and liver. Previous researches have shown that
cell proliferation can be found in subventricular
zone in rat model disposed by the middle cerebral
artery occlusion (MCAO), suggesting that endogenous recovery process is started after stroke
[54–57]. However, endogenous resilience may be
limited due to hostile immune microenvironment
over time [56, 58]. In addition, the delayed
inflammatory response to stroke leads to secondary neurological injury [52, 58]. Insufficient
endogenous stem cells after stroke can result in
weak regeneration of nerve cells in the damaged
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area and slowdown in tissue function recovery.
It is an effective treatment to solve the problem
of endogenous neuronal defects after stroke by
directly injecting exogenous stem cells into the
ischemic area [58–60].
However, paracrine factors (especially exosomes)
appear to play a major therapeutic role in recent
studies, although the therapeutic effects of cell
transplantation can be directly and indirectly
explained by growth factors and cytokines [61–63].
Moreover, Xin et al. have demonstrated increased
generation of posterior nerve cells and oligodendrocytes in stroke-injured areas after intravenous
injection of exosomes containing miRNA-17–92
cluster (Fig. 4) [59]. Symptoms can be effectively

relieved in other systemic diseases after exosomes
are transferred to the site of injury. For example,
cardiac-derived exosomes have been shown to
have cardio-protective effects, stimulate regenerative signals, and participate in repair after
myocardial infarction [64]. The above examples
demonstrate that exosomes-transplantation therapy
could play a practical role in the treatment of
disease. Notably, Kalani found that stem cellderived exosomes are not only as effective as stem
cell transplants, but also overcome the limitations
of ischemic stem cell therapy compared to the
previous cell therapies [7].
4.2 Cell source and delivery path of exosome
transplantation
4.2.1

Fig. 4

miRNA-17–92 cluster-elevated multipotent mesenchymal

stromal cell (MSC) exosomes increase neurogenesis and oligodendrogenesis in the ischemic boundary zone (IBZ). Representative
micrographs show the double stained cells with neuron (NeuN)
and 5-bromodeoxyuridine (BrdU) (A), progenitor (NG2) and BrdU
(B), or mature oligodendrocytes (MBP) and BrdU (C). Compared
with liposome treatment, exosome treatment significantly increased
the percentage of BrdU–NeuN-stained cells, BrdU–NG2-stained
cells, and BrdU–MBP-stained cells in the IBZ in rats after stroke,
and miRNA-17–92 cluster-enriched exosomes (Exo-miR-17–92+)
further increased these double stained cells compared with the
control MSC-derived exosomes (Exo-Con; P < 0.05, respectively).
LP, MCAO rats treated with liposome; EV, MCAO rats treated with
Exo-Con; 17–92, MCAO rats treated with Exo-miR-17–92+. MCAO
indicates middle cerebral artery occlusion. *P < 0.05 compared
with LP. #P < 0.05 compared with EV. Mean ± SE, n = 5/group.
Scale bar = 25 μm. Reproduced from Ref. [65] with permission of
Lippincott Williams & Wilkins.
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Cell source

The cell source and injection path of the exosomes
are also critical for the treatment of stroke. Studies
have shown that exosomes released from stem
cells may activate the self-regenerating process
of injured cells by providing stem cell-like
phenotypes, providing therapeutic potential for a
variety of diseases [66]. For instance, mesenchymal
stem cell (MSC)-derived exosomes have numerous
benefits against stroke by promoting functional
recovery, neurovascular plasticity, neuroprotection,
nerve regeneration, and regulation of peripheral
immune responses. Therefore, the source of stem
cells for exosomes used for stroke treatment needs
to be considered carefully. Embryonic stem
cells (ESCs) have the characteristics of infinite
proliferation, self-renewal and multi-directional
differentiation in vitro, and it can be induced to
differentiate into almost all cell types both in vitro
and in vivo. However, the research on exosomes
derived from embryonic stem cells indicated that
the embryos need to be damaged, and found
that some embryonic exosomes carry infectious
particles, which limits its application [11]. Induced
pluripotent stem cells (IPSCs) can avoid similar
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problems as a source of exosomes, but the application of iPSCs has also encountered obstacles
that may be involved in tumorigenesis [67]. In
recent years, exosomes derived from adult stem
cells have attracted much attention because they
have no significant side effects on recipient cells.
MSCs come from a wide range of sources, not
only in bone marrow, bone, muscle, or adipose
tissue, but also from tissues isolated from the brain,
kidney, liver, and spleen [68]. Moreover, MSCs
are abundantly productive compared to other cells
known to produce exosomes [69]. The exosomes
secreted by endothelial progenitor cells (EPCs)
are rich in miRNA-126 and miRNA-296, and
have an effect of promoting angiogenesis and antiapoptosis. In addition, neural stem cells produce
all major cell types of the central nervous system
including neurons, astrocytes, and oligodendrocytes, and their secreted exosomes are bound
to enhance functional recovery after stroke. Chen
et al. found that human neural stem cells-derived
exosomes produced under hypoxia preconditioning can promote the treatment of stroke [70].
Neural stem cells (NPCs) have stronger differentiation potential and renewal ability than neural
progenitor cells. It is also a prolific producer of
exosomes similar to mesenchymal stem cells.
Adult stem cells may be a good source of cells
for exosomes.
4.2.2

Delivery path

Various forms of exosome delivery route are used
to treat ischemic stroke, such as intravenous/
intra-arterial infusion, intracerebral route, and
intracranial injection. Intracranial injection is a
classic method of injection, which involves injecting
exosomes directly into the injured area. However,
direct injection is traumatic and single exosome
injection can’t do much, otherwise it will cause
an intracranial lesion, and has certain complications such as subdural hematoma, epilepsy.
Intravenous injection has attracted much attention

due to its low damage and convenience as a
common transplant approach. However, high
blood volume in the blood vessels and extremely
fast blood flow rate will lead to insufficient
intracerebral cell concentration. In addition,
exosomes that are not specially treated can be
quickly eliminated by phagocytosis in the reticuloendothelial system (RES), filtered by the
kidneysor the bile excretion as the blood flows
through the body organs, thereby resulting in a
decreased concentration of exosomes in the brain.
This is similar to the result of most stem cells
staying in peripheral organs after intravenous
transplantation. For example, Pluchino found that
after intravenous injection into the experimental
autoimmune encephalomyelitis (EAE) mice model,
only about 3% of the NPCs migrate back to the
central nervous system after 24 hours, whereas
most of the cells are distributed throughout
the body tissues [71]. In addition, for stroke,
intranasal delivery of exosomes is an alternative
choice because of its simple operation and noninvasiveness. The uniqueness of intranasal route
is that it is a non-invasive method, and transmission of the material can bypass the blood–
brain barrier, and the transfer medium are nasal
nerves, such as trigeminal nerve, cerebrospinal
fluid [72–74]. Zhuang found that exosomes
carrying curcumin and activator of transcription
3 (Stat3) inhibitor can delay the EAE disease,
and inhibit the growth of tumors in vivo by
intranasal injection [75]. This experiment demonstrates that exosomes can effectively reach the
central nervous system through the intranasal
route.
4.3 Exosomes as carriers
Drug therapy is a key part of the treatment
routine of ischemic stroke. However, conventional
drug treatment often has some problems, such
as poor water solubility, low cell penetration, and
dispersion in the body. These problems will lead
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to increase of drug dosage by limiting the efficacy
of the drug and increasing the likelihood of side
effects, or wasting medical resources. Thus, in
addition to the further development of drugs, a
reasonable drug delivery system can solve the
current problems, and enable drugs to reach the
injured site safely and effectively. As a natural
nano-scale particulate material, exosomes have
the potential of being material transport carriers
because of their biocompatibility, low immunogenicity, and stable circulation in the blood [76].
In addition, exosomes have significant advantages
over existing drug carriers (such as artificial
liposomes): some proteins on the surface of
exosomes from different cell sources allow the
exosomes to selectively bind to the receptor cells.
Meanwhile, the specific surface molecules of
exosomes can avoid interaction with antibodies
and clotting factors in specific cells [such as
immature dendritic cells (DCs)], avoiding the human
immune response as much as possible. Studies
have found that sustained activation of immune
effectors in some patients help maintain longterm disease stability after receiving autologously
derived exosomes [77, 78].
Studies have shown that small molecule drugs
have a positive effect on the treatment of stroke.
For instance, salidroside promotes the expression
of M2 markers in microglia after stroke, and
protects neurons by promoting polarization of M2
microglia [79]. Moreover, it can reduce the brain
infarct size, and improve neurological function
in animal models. It is an alternative choice for
therapeutic molecules to be delivered to the injury
sites by exosomes. Gao has demonstrated that
curcumin-loaded cRGD-Exo lead to a strong
inhibition of inflammatory response in the lesion
area of ischemic mice (Fig. 5) [80]. Blood–brain
barrier, however, is the major obstacle to traditional
methods of transmission, although damaged
barrier cells caused by stroke will slowly repair
over time. Because of the blood–brain barrier,
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only one drug among the top ten molecules is
a neurological treatment drug according to the
statistics of the world’s top prescription drugs
in 2014 [81]. Exosomes were found to be able to
cross the blood–brain barrier [82], and exosomes
can be used for drug delivery in the nervous
system that requires efficient, non-toxic drugs.
Interestingly, the exosomes are lipid bimolecular
membranes, but they have a hydrophilic core,
which is very important for the delivery of soluble
drugs [83]. At present, there are two methods
for binding molecular drugs to exosomes: 1. Bind
drugs to donor cells, and separate exosomes
containing therapeutic molecules from cells. 2. The
exosomes are first purified from the cells, and
the therapeutic molecules are loaded into the
exosomes by specific methods. These methods
include co-incubation of the exosomes with the
drug, electroporation applied to open a transient
pore in the exosomes, during which time the small
molecule drugs were inhaled into the exosomes
[76], and direct chemical transfection of the
exosomes. In addition, exosome donor cells
can be selected from immature DCs because
exosomes derived from immature DCs only
cause a weaker immune response [84].
Genes can be loaded by exosomes. The
phospholipid bilayer structure of the exosome
surface ensures that the genes present in the
exosomes are protected from degradation during
long-term cycling, and the stability of the contents
is highly maintained to synergize with the recipient
cells. Exosomes can also act on recipient cells by
loading foreign genes. Brain-derived neurotrophic
factor (BDNF) is a protein synthesized in the brain
that is widely distributed in the central nervous
system. It plays a key role in the survival,
differentiation, and growth of neurons during
the development of the central nervous system.
Studies have shown that BDNF can prevent acute
ischemic injury, increase brain tissue repair,
and promote synaptic plasticity [85]. Chen et al.
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Fig. 5

The inhibitory effect of cRGD-Exo-cur on inflammatory response after cerebral ischemia. Intravenous administrations of PBS,

unmodified exosomes, cRGD-Exo, curcumin, or cRGD-Exo-cur were performed on mice receiving 1 h of MCAO and 12 h of reperfusion.
(A) RT-PCR analyses of TNF-α, IL-1β, and IL-6 in the tissue of lesion region were performed 12 h after administration (24 h after
reperfusion). (B) Western blot and (C) quantitative analyses of TNF-α, IL-1β, and IL-6 in the tissue of lesion region were performed 24 h
after administration (36 h after reperfusion). (D) Representative fluorescence images of Iba1 stained microglia at peri-infarct areas 24 h after
administration (36 h after reperfusion). Scale bar, 50 μm. (E) Quantitative analysis showing the fluorescence intensity of Iba1 per cell
corresponding to (D). (F) Western blot and (G) quantitative analyses of p-p65 and cleaved caspase-3 in the tissue of lesion region were
performed 24 h after administration (36 h after reperfusion). The sham groups were used as negative control. Data are expressed as
mean ± SEM, n ≥ 4; *P < 0.05, **P < 0.01, ***P < 0.001 versus the PBS groups, and #P < 0.05, ##P < 0.01 versus the Curcumin groups by one-way
ANOVA. Reproduced from Ref. [80] with permission of Elsevier Sci Ltd.

found that BDNF has neuroprotective effects on
MCAO-treated mice, thus the binding of BDNF
to the modified exosomes can be introduced into
the injured tissues to support the nerves in the
damaged area [86]. Transferring these genes
into donor cells by certain means (e.g. genetic
engineering) can improve tissue ischemia in the

intracranial area by producing exosomes to induce
regeneration of blood vessels.

5

Conclusion

In summary, we briefly discussed the physiology,
origin, disease-related mechanisms, and thera-
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peutic potential of exosomes. However, many
problems related to exosomes still exist. For
example, it is unclear what the molecular
mechanism is, by which MVB fusion sites are
defined in the plasma membrane, how receptor
cells specifically select exosomes, and what the
mechanisms of fusion is. Although the differential
centrifugation operation is simple, and more
vesicles can be obtained to meet the experimental
needs, some problems haven’t been solved.
For example, the centrifugation process is timeconsuming, and the recovery rate is unstable. In
addition, repeated centrifugation operations can
also result in damage to the vesicles, which can
degrade quality. Commercial kits capture more
exosomes from the cell supernatant, but the purity
is questioned. Exosomes treatment offers new
insights into stroke treatment by minimizing
adverse effects, which may replace cell-based
therapies. However, it is likely, as cell-based
therapies, most of the exosomes are distributed
in other organs such as liver. How to effectively
improve the targeting of exosomes will be the
key to therapeutic applications of exosomes.
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